A new research document with title ‘Colorectal Cancer – Pipeline Review, H1 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Bionomics Ltd, Bionovis SA, Biotecnol Ltd
The report will help user gain market insights, future trends and growth prospects for forecast period of 2017 – 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/560250-colorectal-cancer-pipeline-review
Colorectal Cancer – Pipeline Review, H1 2017
latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer – Pipeline Review, H1 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 25, 108, 137, 10, 173, 26 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 18, 9, 28 and 5 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
3-V Biosciences Inc
AB Science SA
AbGenomics International Inc
Adamed Sp z oo
Aduro BioTech Inc
Advenchen Laboratories LLC
Antibe Therapeutics Inc
APEIRON Biologics AG
ARMO Biosciences Inc
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
Aurobindo Pharma Ltd
AVEO Pharmaceuticals Inc
B Cell Design SAS
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
BeiGene (Beijing) Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
BeyondSpring Pharmaceuticals Inc
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/560250-colorectal-cancer-pipeline-review
Table of Contents
Table of Contents 2
Colorectal Cancer – Overview 12
Colorectal Cancer – Therapeutics Development 13
Colorectal Cancer – Therapeutics Assessment 66
Colorectal Cancer – Companies Involved in Therapeutics Development 94
Colorectal Cancer – Drug Profiles 223
Colorectal Cancer – Dormant Projects 1708
Colorectal Cancer – Discontinued Products 1725
Colorectal Cancer – Product Development Milestones 1730
Appendix 1745List of Tables
Number of Products under Development for Colorectal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/560250-colorectal-cancer-pipeline-review
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=560250
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218